Alemtuzumab and fatigue Patient Reports February 10, 2010

Alemtuzumab Side Effects Report #5971708-1
Alemtuzumab side effect was reported by a Physician from GERMANY on Nov 10, 2008. Female patient, 56 years of age, was diagnosed with t-cell lymphoma and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: asthenia, blood potassium decreased, diarrhoea, fatigue, pyrexia. Alemtuzumab dosage: unknown. During the same period patient was treated with PREDNISONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PEGFILGRASTIM, CARMUSTINE, ETOPOSIDE, CYTARABINE. Patient was hospitalized. Patient recovered.

Alemtuzumab Side Effects Report #6119038-1
Alemtuzumab side effect was reported by a Physician from GERMANY on Mar 10, 2009. Female patient, 56 years of age, was diagnosed with t-cell lymphoma and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: asthenia, blood potassium decreased, diarrhoea, fatigue, pyrexia. Alemtuzumab dosage: unknown. During the same period patient was treated with PREDNISONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PEGFILGRASTIM, CARMUSTINE, ETOPOSIDE, CYTOSINE ARABINOSIDE. Patient was hospitalized. Patient recovered.

Alemtuzumab Side Effects Report #6119104-0
Alemtuzumab side effect was reported by a Physician from GERMANY on Mar 10, 2009. Female patient, 56 years of age, was diagnosed with t-cell lymphoma and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: asthenia, blood potassium decreased, diarrhoea, fatigue, pyrexia. Alemtuzumab dosage: unknown. During the same period patient was treated with PREDNISONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PEGFILGRASTIM, CARMUSTINE, ETOPOSIDE, CYTARABINE. Patient was hospitalized. Patient recovered.